| Interventions to reduce stigma related to mental illnesses in educational institutes: A systematic review A Waqas, S Malik, A Fida, N Abbas, N Mian, S Miryala, AN Amray, Z Shah, ... Psychiatric Quarterly 91 (3), 887-903, 2020 | 77 | 2020 |
| Bispecific T-cell engager (BiTE) antibody based immunotherapy for treatment of relapsed refractory multiple myeloma (RRMM): A systematic review of preclinical and clinical trials Z Shah, MN Malik, SS Batool, S Kotapati, A Akhtar, O ur Rehman, ... Blood 134, 5567, 2019 | 13 | 2019 |
| Intraperitoneal Hematoma After Femoral Catheterization: A Case Report and Literature Review Z Shah, I Khan, ID de Oliveira Santo Cureus 14 (5), 2022 | 12 | 2022 |
| The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review R Khanam, OS Ashruf, SHB Waqar, Z Shah, S Batool, R Mehreen, ... Antibodies 12 (2), 38, 2023 | 8 | 2023 |
| Emerging targets and cellular therapy for relapsed refractory multiple myeloma: a systematic review LL George, SR Deshpande, MJ Cortese, EK Kendall, A Chattaraj, Z Shah, ... Clinical Lymphoma Myeloma and Leukemia 21 (11), 741-751, 2021 | 8 | 2021 |
| Concomitant use of blinatumomab and donor lymphocyte infusion for post-transplant relapsed CD19 positive acute lymphoblastic leukemia: systematic review C Durer, S Durer, M Shafqat, Z Shah, M Sadiq, MA Fraz, MQ Ahmad, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 8 | 2018 |
| Role of Venetoclax in the treatment of relapsed and refractory multiple myeloma H Ehsan, A Wahab, Z Shah, MK Sana, A Masood, A Rafae, H Hashmi Journal of Hematology 10 (3), 89, 2021 | 7 | 2021 |
| Evidence-based supportive care in multiple myeloma A Qureshi, MJ Tariq, Z Shah, M Abu Zar, S Aslam, A Rafae, M Shafqat, ... Journal of Community Hospital Internal Medicine Perspectives 10 (4), 313-317, 2020 | 5 | 2020 |
| Systematic review and meta-analysis of the accuracy and applicability of blood-based multi-cancer early detection (MCED) in the general population. JH Park, Y Oh, LIY Chung, R Duan, TA Djunadi, SM Yoon, Z Shah, ... Journal of Clinical Oncology 41 (16_suppl), 3069-3069, 2023 | 4 | 2023 |
| Management of relapsed hairy cell leukemia: a systematic review of novel agents and targeted therapies R Siddiqui, M Sardar, M Shahzad, J Jose, I Selene, Z Shah, A Qureshi, ... Clinical Lymphoma Myeloma and Leukemia 21 (10), 659-666, 2021 | 3 | 2021 |
| Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma W Tai, A Wahab, D Franco, Z Shah, A Ashraf, QUA Abid, YN Mohammed, ... Antibodies 11 (2), 22, 2022 | 2 | 2022 |
| Allogeneic hematopoietic stem cell transplant in rare hematologic disorders: a single center experience from Pakistan M Khan, R Iftikhar, T Ghafoor, F Hussain, QN Chaudhry, SK Mahmood, ... Bone Marrow Transplantation 56 (4), 863-872, 2021 | 2 | 2021 |
| Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation A Wahab, A Rafae, MS Faisal, K Mushtaq, H Ehsan, M Khakwani, ... Expert Review of Hematology 13 (12), 1333-1347, 2020 | 2 | 2020 |
| Role of B-Cell Maturation Antigen (BCMA) targeted immunotherapies in relapsed and refractory multiple myeloma-a systematic review Z Shah, SS Batool, HM Fazeel, MN Malik, M Sadiq, SF Hassan, TIS Syed, ... Blood 134, 5597, 2019 | 2 | 2019 |
| Efficacy and toxicity profile of elotuzumab for multiple myeloma: A systematic review and meta-analysis F Jamil, M Shafqat, S Samuel, Z Shah, C Durer, S Durer, M Sadiq, ... Blood 132, 5640, 2018 | 2 | 2018 |
| The use of checkpoint inhibitors before and after allogeneic stem cell transplantion: a double-edged sword AY Khan, A Ijaz, M Usman, MJ Tariq, MA Fraz, MJ Khalil, C Durer, S Durer, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 2 | 2018 |
| Histone Deacetylase Inhibitors in Myelodysplastic Syndrome II Selene, JA Jose, M Sardar, Z Shah, M Shafqat, W Faridi, MN Malik, ... Blood 132, 5528, 2018 | 2 | 2018 |
| A systematic review and meta-analysis: efficacy and toxicity profile of ixazomib for treatment of multiple myeloma M Shafqat, F Jamil, Z Shah, AY Khan, S Durer, C Durer, S Aslam, ... Blood 132, 5639, 2018 | 2 | 2018 |
| Liquid biopsies and minimal residual disease in myeloid malignancies S Allam, K Nasr, F Khalid, Z Shah, MZ Khan Suheb, S Mulla, S Vikash, ... Frontiers in oncology 13, 1164017, 2023 | 1 | 2023 |
| Intestinal microbiome diversity and clinical outcomes with multiple myeloma: A systematic review. A Ashraf, S Nabeel, Z Ahmed, AA Farooqui, S Rehman, S Batool, Z Shah, ... Journal of Clinical Oncology 38 (15_suppl), e20542-e20542, 2020 | 1 | 2020 |
Faiz AnwerCleveland Clinic, Taussig Cancer CenterVerified email at ccf.org
